Altimmune ALT
NASDAQ ALT
$2.86 -0.11 (-3.70%)
At close: Sep 30, 2026 · 4:00 PM EDT

Altimmune (ALT) Current Deferred Revenue (2016 - 2018)

Updated

Altimmune's Current Deferred Revenue was $19,753 in Q3 2018, unchanged from $19,753 a year earlier and down 38.8% from the prior quarter.

Analysis

Altimmune (ALT) Current Deferred Revenue (2016 - 2018) Analysis & Trends

From Q4 2016 onward, Altimmune has reported Current Deferred Revenue for 7 quarters.

  • In earlier years, Current Deferred Revenue was $19,753 in FY2016.
  • Quarterly Current Deferred Revenue has moved between $19,753 (Q4 2016) and $44,753 (Q1 2018) over five years.
  • Per Business Quant data, ALT's Current Deferred Revenue in the three quarters before Q3 2018 was $32,253 (Q2 2018), $44,753 (Q1 2018) and $19,753 (Q4 2017).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Altimmune 577.59 Mn 577.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 19,753.00
Jun 30, 2018 32,253.00
Mar 31, 2018 44,753.00
Dec 31, 2017 19,753.00
Sep 30, 2017 19,753.00
Jun 30, 2017 32,253.00
Dec 31, 2016 19,753.00
API Access

Altimmune Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ALT&period=max&api_key=YOUR_API_KEY